The Experts below are selected from a list of 60 Experts worldwide ranked by ideXlab platform
Boonnam Blackwell - One of the best experts on this subject based on the ideXlab platform.
-
subchronic studies of Tripelennamine in fischer 344 rats
Journal of the American College of Toxicology, 1991Co-Authors: Carlton D Jackson, Boonnam BlackwellAbstract:The purpose of this study was to determine the subchronic toxicity of the antihistamine Tripelennamine and to allow selection of appropriate doses for chronic studies. Male and female Fischer 344 rats were administered Tripelennamine hydrochloride in the feed at dose levels of 0, 300, 600, 1200, 2400, and 6000 ppm (as the free amine) for 14 days or at dose levels of 0, 150, 300, 600, 1200, and 2400 ppm for 90 days. In the 14-day study, all of the animals in the 6000 ppm groups died. All others survived until killed. Final body weights of treated groups were reduced from 3% to 25%. Cytoplasmic vacuolization of the liver was observed. In the 90-day study, a dose-dependent reduction in body weight gain was produced by Tripelennamine, with a 10% reduction in final body weight occurring between 300 and 600 ppm. Reductions in various organ weights were found to be correlated with reduced final body weights. Tripelennamine produced cytoplasmic vacuolization or fatty change in the liver, cytomegaly and granular b...
-
subchronic studies of Tripelennamine in b6c3f1 mice
Journal of the American College of Toxicology, 1991Co-Authors: Carlton D Jackson, Boonnam BlackwellAbstract:The subchronic toxicity of Tripelennamine hydrochloride was determined to provide data for selecting dose levels for a 2-year study in mice. Male and female B6C3F1 mice were administered the drug in their feed at dose levels of 0, 150, 300, 600, 1200, and 2400 ppm (calculated as free amine) for 14 days or 0, 300, 600, 1200, 2400, and 4800 ppm for 90 days. Little toxicity was observed in the 14-day study. In the 90-day study, final body weights of males and females of the 4800 ppm groups were reduced 14% and 4%, respectively. Clinical observations and necropsy findings were unremarkable in the 90-day study. Decreased heart weight/brain weight ratios in males and increased liver weight/brain weight ratios in females were seen at dose levels as low as 600 ppm. Histologically, changes consisting of cytomegaly, karyomegaly, and cytoplasmic vacuolization of the liver, mild to severe cytomegaly and necrosis of parotid salivary gland acinar cells, and a mild degree of vacuolar degeneration of the bronchial epithe...
Miwa Misawa - One of the best experts on this subject based on the ideXlab platform.
-
Interactions between H1-antagonists and opioids: a drug discrimination study
Psychopharmacology, 1997Co-Authors: Tsutomu Suzuki, Miwa Misawa, Tomohisa Mori, Minoru Tsuji, Kenji OnoderaAbstract:We previously demonstrated that combination of opioids, pentazocine and dihydrocodeine, with the histamine H1-receptor antagonists Tripelennamine and chlorpheniramine could enhance their rewarding effects in rats. In the present study, the effects of combined treatment with opioids and H1-antagonists on discriminative stimulus effects were examined in rats trained to discriminate between cocaine (10 mg/kg) or morphine (3.0 mg/kg) and saline, since it is believed that discriminative stimulus effects of abused drugs are related to their rewarding effects. Tripelennamine and chlorpheniramine, but not pentazocine or dihydrocodeine, generalized to the discriminative stimulus effects of cocaine. Pentazocine (3.0 mg/kg) and dihydrocodeine (5.6 mg/kg) significantly potentiated the cocaine-like discriminative stimulus effects of low doses of Tripelennamine and chlorpheniramine, respectively. On the other hand, pentazocine and dihydrocodeine, but not Tripelennamine or chlorpheniramine, generalized to the discriminative stimulus effects of morphine. Neither 1.0 or 3.0 mg/kg Tripelennamine nor chlorpheniramine affected the morphine-like discriminative stimulus effects of pentazocine and dihydrocodeine, respectively. These results suggest that the potentiation of the cocaine-like discriminative stimulus effects of H1-antagonists by opioids may be involved in the enhanced rewarding effects of combinations of opioids and H1-antagonists.
-
Potentiation of pentazocine conditioned place preference by Tripelennamine in rats
Psychopharmacology, 1991Co-Authors: Tsutomu Suzuki, Yoshikazu Masukawa, Yoshinao Shiozaki, Miwa MisawaAbstract:The effects of Tripelennamine on place preference conditioning in rats with pentazocine were investigated. Pentazocine at a dose of 2 mg/kg (IP) slightly, but not significantly, induced a place preference. Concurrent dosing of pentazocine (2 mg/kg, IP) and Tripelennamine (2.5 mg/kg, SC) significantly and prominently produced a place preference, although administration of Tripelennamine (2.5 mg/kg, SC) alone did not. Chronic infusion of a dopamine D_1 receptor antagonist, SCH23390 (1.0 mg/kg/day) during conditioning abolished the appetitive effect of pentazocine potentiated by the combination with Tripelennamine. In conclusion, it is suggested that the dopaminergic system, especially at the D_1 receptor, plays an important role in the potentiation effect of Tripelennamine on the pentazocine-induced place preference.
Carlton D Jackson - One of the best experts on this subject based on the ideXlab platform.
-
subchronic studies of Tripelennamine in fischer 344 rats
Journal of the American College of Toxicology, 1991Co-Authors: Carlton D Jackson, Boonnam BlackwellAbstract:The purpose of this study was to determine the subchronic toxicity of the antihistamine Tripelennamine and to allow selection of appropriate doses for chronic studies. Male and female Fischer 344 rats were administered Tripelennamine hydrochloride in the feed at dose levels of 0, 300, 600, 1200, 2400, and 6000 ppm (as the free amine) for 14 days or at dose levels of 0, 150, 300, 600, 1200, and 2400 ppm for 90 days. In the 14-day study, all of the animals in the 6000 ppm groups died. All others survived until killed. Final body weights of treated groups were reduced from 3% to 25%. Cytoplasmic vacuolization of the liver was observed. In the 90-day study, a dose-dependent reduction in body weight gain was produced by Tripelennamine, with a 10% reduction in final body weight occurring between 300 and 600 ppm. Reductions in various organ weights were found to be correlated with reduced final body weights. Tripelennamine produced cytoplasmic vacuolization or fatty change in the liver, cytomegaly and granular b...
-
subchronic studies of Tripelennamine in b6c3f1 mice
Journal of the American College of Toxicology, 1991Co-Authors: Carlton D Jackson, Boonnam BlackwellAbstract:The subchronic toxicity of Tripelennamine hydrochloride was determined to provide data for selecting dose levels for a 2-year study in mice. Male and female B6C3F1 mice were administered the drug in their feed at dose levels of 0, 150, 300, 600, 1200, and 2400 ppm (calculated as free amine) for 14 days or 0, 300, 600, 1200, 2400, and 4800 ppm for 90 days. Little toxicity was observed in the 14-day study. In the 90-day study, final body weights of males and females of the 4800 ppm groups were reduced 14% and 4%, respectively. Clinical observations and necropsy findings were unremarkable in the 90-day study. Decreased heart weight/brain weight ratios in males and increased liver weight/brain weight ratios in females were seen at dose levels as low as 600 ppm. Histologically, changes consisting of cytomegaly, karyomegaly, and cytoplasmic vacuolization of the liver, mild to severe cytomegaly and necrosis of parotid salivary gland acinar cells, and a mild degree of vacuolar degeneration of the bronchial epithe...
Barbara L Slifer - One of the best experts on this subject based on the ideXlab platform.
-
the role of dopamine in the effects of pentazocine and Tripelennamine
Pharmacology Biochemistry and Behavior, 1990Co-Authors: Thomas J Hudzik, Barbara L SliferAbstract:Abstract CNS dopamine has been suggested as a mediator in the effects of many drugs of abuse. The present study was conducted to assess the potential dopaminergic activity of pentazocine and Tripelennamine combinations (T's and Blues). The effects of pentazocine and Tripelennamine, administered alone and in combination with several dopaminergic drugs, on milk drinking were assessed in the rat. Both the opioid and antihistamine were tested in combination with apomorphine and haloperidol. Pentazocine was also tested in combination with the D 1 - and D 2 -receptor selective antagonists SCH 23390 and raclopride, and with the D 2 -receptor agonist quinpirole. Tripelennamine was additionally tested in combination with methamphetamine. Haloperidol and quinpirole pretreatment produced leftward shifts in the pentazocine dose-effect curve while raclopride and SCH 23390 shifted the opioid curve to the right. Doses of apomorphine shifted Tripelennamine's dose-effect curve to the left, Tripelennamine enhanced the effects of methamphetamine, but haloperidol did not alter the antihistamine's effects. These data suggest dopaminergic involvement in the effects of the opioid and antihistamine.
Tsutomu Suzuki - One of the best experts on this subject based on the ideXlab platform.
-
Interactions between H1-antagonists and opioids: a drug discrimination study
Psychopharmacology, 1997Co-Authors: Tsutomu Suzuki, Miwa Misawa, Tomohisa Mori, Minoru Tsuji, Kenji OnoderaAbstract:We previously demonstrated that combination of opioids, pentazocine and dihydrocodeine, with the histamine H1-receptor antagonists Tripelennamine and chlorpheniramine could enhance their rewarding effects in rats. In the present study, the effects of combined treatment with opioids and H1-antagonists on discriminative stimulus effects were examined in rats trained to discriminate between cocaine (10 mg/kg) or morphine (3.0 mg/kg) and saline, since it is believed that discriminative stimulus effects of abused drugs are related to their rewarding effects. Tripelennamine and chlorpheniramine, but not pentazocine or dihydrocodeine, generalized to the discriminative stimulus effects of cocaine. Pentazocine (3.0 mg/kg) and dihydrocodeine (5.6 mg/kg) significantly potentiated the cocaine-like discriminative stimulus effects of low doses of Tripelennamine and chlorpheniramine, respectively. On the other hand, pentazocine and dihydrocodeine, but not Tripelennamine or chlorpheniramine, generalized to the discriminative stimulus effects of morphine. Neither 1.0 or 3.0 mg/kg Tripelennamine nor chlorpheniramine affected the morphine-like discriminative stimulus effects of pentazocine and dihydrocodeine, respectively. These results suggest that the potentiation of the cocaine-like discriminative stimulus effects of H1-antagonists by opioids may be involved in the enhanced rewarding effects of combinations of opioids and H1-antagonists.
-
Potentiation of pentazocine conditioned place preference by Tripelennamine in rats
Psychopharmacology, 1991Co-Authors: Tsutomu Suzuki, Yoshikazu Masukawa, Yoshinao Shiozaki, Miwa MisawaAbstract:The effects of Tripelennamine on place preference conditioning in rats with pentazocine were investigated. Pentazocine at a dose of 2 mg/kg (IP) slightly, but not significantly, induced a place preference. Concurrent dosing of pentazocine (2 mg/kg, IP) and Tripelennamine (2.5 mg/kg, SC) significantly and prominently produced a place preference, although administration of Tripelennamine (2.5 mg/kg, SC) alone did not. Chronic infusion of a dopamine D_1 receptor antagonist, SCH23390 (1.0 mg/kg/day) during conditioning abolished the appetitive effect of pentazocine potentiated by the combination with Tripelennamine. In conclusion, it is suggested that the dopaminergic system, especially at the D_1 receptor, plays an important role in the potentiation effect of Tripelennamine on the pentazocine-induced place preference.
